South San Francisco, United States
Abdera Therapeutics Inc., founded in 2021, is a burgeoning player in the fields of Biotechnology, Health Care, and Life Sciences, with its headquarters in the United States. The company is at the forefront of developing next-generation targeted radiation therapies, utilizing a proprietary modular technology platform. This innovative platform enables the delivery of radioisotopes to precisely target and destroy tumor cells, reducing collateral damage to healthy tissues.
The company recently secured a $142.00M Series B investment on April 20, 2023. This round was backed by prominent investors including Qiming Venture Partners USA, Versant Ventures, Amplitude Ventures, RTW Investments, VenBio Partners, Viking Global Investors, and Northview LifeSciences. The influx of capital is earmarked to accelerate the development of their therapies, which aim to offer new hope for cancer patients with limited treatment options.
